Thalidomide and its metabolites have no effect on human lymphocyte proliferation

International Archives of Allergy and Immunology

Volumn 111, Issue 1, 1996, Pages 13-17

  Santos Mendoza, T ^a   Favila Castillo, L ^a   Oltra, A ^a   Tamariz J ^a   Labarrios, F ^a   Estrada Parra, S ^a   Estrada Garcia I ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Lymphocyte proliferation; Thalidomide; Thalidomide metabolites

Indexed keywords

CONCANAVALIN A; THALIDOMIDE;

ADULT; ARTICLE; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA; PRIORITY JOURNAL; RABBIT;

EID: 0029831034     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237338     Document Type: Article

References (14)

1. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965:6:303-306.
2. Wood PMD, Proctor SJ: The potential use of thalidomide in the therapy of graft-versus-host disease. A review of clinical and laboratory information. Leuk Res 1990;14:395-399.
3. Knop J, Bonsmann G, Happle R: Thalidomide in the treatment of sixty cases of chronic discoid lupus erythaematosus. Br J Dermatol 1983:108: 461-466.
4. Sampaio EP, Samo EN, Galilly R, Colin ZA, Kaplan G: Thalidomide selectively inhibits tumour necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173: 699-703.
5. Gad SM, Shannon FJ, Krotoski WA, Hastings RC: Thalidomide induces imbalances in T-lym-phocytc subpopulations in the circulating blood of healthy males. Lcpr Rev 1985;56:35-39.
6. Neubert R, Nogueira AC, Neubert D: Thalidomide dérivâtes and the immune system. I, Changes in the pattern of intcgrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67:1-17.
7. Roath S, Elves MW, Israels MCG: Effects of thalidomide and its derivatives on human leukocytes cultures in vitro. Lancet 1963:i:249-250.
8. Coulson AJ, Summers LJ, Lindhal-Kiessling K, Tucker D, Heilman K: The effect of two soluble thalidomide dérivâtes on lymphocyte stimulation. Clin Exp Immunol 1970;7:241-247.
9. Kennan RJ, Eiras G, Burckhart GJ: Immunosuppressive properties of thalidomide. Transplantation 1991;52:908-910.
10. Chemie Grünenthal GmbH Brit 768,821,1957. Chem Abstr 1957;51:15595h.
11. Chen TL, Vogelsand GB, Petty BG, Brundett RB, Noe DA, Santos GW, Colvin OM: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17:402-405.
12. Schumacher H, Smith RL, Williams RT: The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965;25:338-351.
13. Schumacher II, Blake DA, Gillette JR: Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968;160:201-211.
14. Fabro S: Biochemical basis of thalidomide teratogenicity; in Juchau MR (ed): The Biochemical Basis of Chemical Teratogenesis. Amsterdam, Elsevier North Holland, 1981, pp 159- 178.